Q5135 – Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ5135
- Long description
- Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
- Short description
- Inj, tyenne, 1 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- ASC
- Approved for ambulatory surgical centers
- Added
- October 1, 2024
- Last change
- October 1, 2024 – No change
Frequently asked questions
What is HCPCS code Q5135?
Q5135 is a HCPCS Level II code for injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg.
Does Medicare cover Q5135?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q5127 – Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128 – Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
- Q5129 – Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130 – Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5131 – Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Q5132 – Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q5133 – Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5134 – Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
- Q5136 – Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
- Q5137 – Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
- Q5138 – Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
- Q5139 – Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
- Q5140 – Injection, adalimumab-fkjp, biosimilar, 1 mg
- Q5141 – Injection, adalimumab-aaty, biosimilar, 1 mg
- Q5142 – Injection, adalimumab-ryvk biosimilar, 1 mg
- Q5143 – Injection, adalimumab-adbm, biosimilar, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.